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Abstract
Background: Recent advances in the treatment of cancer have focused on targeting genomic aberrations with
selective therapeutic agents. In rare tumors, where large-scale clinical trials are daunting, this targeted genomic
approach offers a new perspective and hope for improved treatments. Cancers of the ampulla of Vater are rare
tumors that comprise only about 0.2% of gastrointestinal cancers. Consequently, they are often treated as either
distal common bile duct or pancreatic cancers.
Methods: We analyzed DNA from a resected cancer of the ampulla of Vater and whole blood DNA from a 63
year-old man who underwent a pancreaticoduodenectomy by whole genome sequencing, achieving 37× and 40×
coverage, respectively. We determined somatic mutations and structural alterations.
Results: We identified relevant aberrations, including deleterious mutations of KRAS and SMAD4 as well as a
homozygous focal deletion of the PTEN tumor suppressor gene. These findings suggest that these tumors have a
distinct oncogenesis from either common bile duct cancer or pancreatic cancer. Furthermore, this combination of
genomic aberrations suggests a therapeutic context for dual mTOR/PI3K inhibition.
Conclusions: Whole genome sequencing can elucidate an oncogenic context and expose potential therapeutic
vulnerabilities in rare cancers.
Background
Advances in treatments for cancer have generally come
incrementally because novel treatments are subjected to
large prospective randomized clinical trials. In these stu-
dies, several hundred patients are randomized to one
treatment arm or another and the treatment associated
with the best outcome is advanced. This method has
worked well for relatively common cancers, including
breast and colon cancers. This approach, however, falls
short when one is faced with rare cancers such that pro-
spective trials involving large numbers of patients are diffi-
cult or impossible to conduct. In these cases, oncologists
may choose chemotherapy regimens because the rare
tumor is thought to be similar to a more common cancer
for which an accepted standard treatment exists. Such is
the case with cancers of the ampulla of Vater. These can-
cers account for only 0.2% of gastrointestinal cancers and
approximately 7% of periampullary tumors. Periampullary
tumors arise from either pancreatic ductal epithelium, the
distal common bile duct, the duodenal mucosa, or the
ampulla of Vater. When resectable, ampullary cancers are
treated like pancreatic cancers with a pancreaticoduode-
nectomy. When they present at an advanced metastatic
stage, there is little information guiding choices for che-
motherapy regimens. Although they represent a minority
in such trials, patients with ampullary cancers are often
included in clinical trials of patients with biliary tract can-
cers, so these patients are often treated with gemcitabine
and cisplatin [1].* Correspondence: mdemeure@tgen.org1Integrated Cancer Genomics Division, Translational Genomics Research
Institute, 445 N. Fifth Ave, Phoenix, AZ 85004, USA
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Genomic technologies have resulted in some limited but
remarkable advances in cancer treatment. Prior to the dis-
covery of the Philadelphia chromosome and the identifica-
tion of the BCR/ABL fusion protein leading to the
development of imatinib, chronic myelogenous leukemia,
a relatively rare form of the disease, was nearly uniformly
fatal. Treatment was a bone marrow transplant with its
attendant high risks of both morbidity and death. Treat-
ment with imatinib, a tyrosine kinase inhibitor, can induce
remission in approximately 87% of patients with greatly
reduced risks of complications [2]. Imatinib was subse-
quently also found to be remarkably effective against gas-
trointestinal stromal tumors [3]. Other targeted drugs that
have recently been shown to have efficacy in the setting of
an indentified genomic aberration include vismodegib in
advanced basal cell skin cancers harboring mutations
in PTCH1, and vemurafenib in patients with advanced
melanoma exhibiting a V600E mutation in the BRAF
(v-raf murine sarcoma viral oncogene homolog B1) gene
product [4,5].
The rapid advancement of genomic technologies offers
the possibility to tailor chemotherapy based on an in-
depth analysis of a limited number of tumor samples. The
advent of next generation sequencing technologies has
now paved the way for near complete interrogation of
tumor genomes, providing the first opportunity for effi-
cient global genomic tumor profiling at the point muta-
tion, copy number, and breakpoint dimensions of the
cancer genome. At a time in which there is an increasing
array of chemotherapy drugs targeting aberrant molecular
pathways, individualized genomic analysis to aid treatment
decisions is quickly becoming feasible. Such an approach
seems particularly well suited to the treatment of rare can-
cers for which there is a paucity of other clinical data to
guide therapy. To demonstrate the potential clinical utility
of individualized genomic analysis in patients with rare
cancers, we applied whole genome sequencing to the
tumor of a 63-year-old man with a resected cancer of the
ampulla of Vater and identified therapeutic targets distinct
from what would have been targeted based on existing
literature.
Materials and methods
Samples
Written informed consent was obtained and the patient
samples were collected for research purposes at Banner
Good Samaritan Medical Center, Phoenix, Arizona. The
study was approved by the Western Institutional Review
Board (WIRB) and was conducted in accordance with the
1996 Declaration of Helsinki. This was a study entitled,
‘Pancreas Cancer Biospecimens Repository’ (WIRB®
Protocol #20040832). Informed consent was obtained
from the patient with cancer of the ampulla of Vater,
including written consent for collection of the tissue and
whole blood samples as well as clinical information and
for genetic analysis of the specimens. The samples were
then anonymized and assigned a unique identifier. Sam-
ples included fresh frozen tumor tissue collected within 20
minutes after surgical resection. Whole blood was
obtained before the start of the operation at the time of
induction of anesthesia. Histopathological analysis of the
frozen specimen was quality assessed and determined to
contain approximately 60% tumor cellularity. DNA and
RNA were extracted from frozen tissue and whole blood
using the Qiagen All Prep kit (Germantown, MD, USA)
using the manufacturer’s recommendations.
Next generation sequencing
To facilitate whole genome next generation sequencing,
we utilized the Life Technologies SOLiD™ (version 3)
technology with mate-pair chemistry using the manufac-
turer’s recommendations (Carlsbad, CA, USA). Briefly, 20
µg of genomic DNA is mechanically sheared to an average
fragment size of 1.5 kb using the HydroShear. These size-
selected fragments are then end repaired and circularized
around a long mate-pair adaptor by nicked ligation. Nick
translation is then used to displace the nick roughly 70 bp
from either side of the internal adaptor. A nuclease reac-
tion linearizes these fragments. SOLiD™ sequencing-
specific sequencing adaptors are then ligated to the ends
of these fragments. We prepared two independent 1.5 kb
mate-pair libraries from the patient’s constitutional (germ-
line) DNA, and two independent mate-pair libraries from
the patient’s tumor DNA. Following PCR amplification,
these mate-pair libraries are then used as templates in
emulsion PCR reactions using SOLiD™ proprietary
sequencing beads to generate clonal single molecule
templated beads. Subsequently, an average of 500,000 tem-
plated beads are enriched and deposited onto SOLiD™
flowcells for massive ligation-based sequencing to generate
50 bp × 50 bp mate-pair sequences per bead. For this
germline/tumor pair, we sequenced an average of one
billion beads per library, thus generating two billion mate-
pair reads for germline and two billion mate-pair reads
for tumor.
Next generation sequencing data processing
Raw next generation sequencing data in the form of
csfasta and qual files are used to align 50 bp × 50 bp
paired end reads from either the patient germline genome
sequence or tumor genome sequence to the reference
human genome (NCBI build 36, hg18). For alignment, we
utilized the Life Technologies BioScope version 1.3 soft-
ware suite, which is based upon a seed-and-extend algo-
rithm [6]. Compressed binary sequence alignment/map
(BAM) formatted output files for germline and tumor
genome alignments are generated and PCR duplicates are
subsequently removed using the Picard Tools.
Demeure et al. Genome Medicine 2012, 4:56
http://genomemedicine.com/content/4/7/56
Page 2 of 10
Next generation sequencing data analysis
Somatic single nucleotide variants
We employed two different algorithms. The first algo-
rithm (SolSNP) [7] detects a SNP variant by comparing
two discrete distributions. It compares the distance of the
discrete sampled distribution of the base-pair pileup on
each strand to the expected distributions (according to
ploidy), and determines the genotype call. This is done
using a Kolmogorov-Smirnov-like distance measure
based on both the base (that is, reference or alternative
base) as well as the confidence in the base called (that is,
the quality score of each base in the pileup). If the gen-
ome is haploid, two expected pileups are created at each
position: one consisting of only the reference base
(a ‘homozygous-reference’ pileup) and another consisting
of only the alternative base (a ‘homozygous non-reference’
pileup). The confidence of each pileup position is kept
the same. The expected pileup that has the minimal
Kolmogorov-Smirnov distance to the sampled pileup is
considered to be the genotype of the locus on the strand.
In diploid genomes, SolSNP also considers a pileup half of
which is made up of the reference bases and the other half
made of alternative bases (a heterozygous pileup). A locus
on the chromosome is called a SNP if a variant genotype
(either ‘homozygous non-reference’ or heterozygous) is
detected on both strands. SolSNP can restrict its calls to
loci where the genotype calls on both strands are identical.
This is achieved by passing the ‘Genotype Consensus’
value to the parameter ‘STRAND_MODE’. In this mode,
the tool is able to produce genotype calls as well as var-
iants. The second algorithm (Mutation Walker) calculates
a test of proportions for the tumor/normal set to construct
a test-statistic for reads in the forward direction and the
reverse detection separately. The minimum of these two
comparisons is used as the reported test-statistic, ensuring
evidence is found in both the normal and reverse detec-
tion. Sites with evidence in the normal are filtered from
the final report so as to reduce false positives arising from
under-sampled polymorphic germline events. Calls com-
mon to both the algorithms were considered for further
examination. To reduce the false negative rate, two sets of
common calls were made. One was made with a strict and
the other with a lenient set of parameters for both the
algorithms. Both the sets were visually examined for false
positives, which were then filtered to get a final list of true
single nucleotide variants.
Indel detection
For detecting somatic indels we employed a two-step
strategy. In the first step, we removed reads from the
tumor sample BAM whose insert size lay outside the inter-
val (500,5000) for SOLiD™. Genome Analysis Toolkit [8]
was then used to generate a list of potential small indels
from this BAM. A customized perl script, which used the
Bio-SamTools library from BioPerl [9], then took these
indel positions and for each of the indels looked at the
region in the germline sample consisting of five bases
upstream of the start and five bases downstream of the
end of the indel. An indel was determined to be somatic
only if there was no indel detected in the region under
consideration.
Structural variants
Structural variants were analyzed by comparing two
sources of information: relative normal/tumor read-level
coverage and anomalously mapping read pairs. Assessing
structural variants by read-level coverage is termed
copy-number analysis since it is parallel in concept to
microarrays. In copy number analysis, gains and losses
were determined by calculating the log2 difference in
normalized coverage between tumor and germline. Briefly,
we investigated regions in 100 bp windows where the cov-
erage in the germline was between 0.1 and 10 of the mode
coverage in order to remove regions with high degrees of
repeat sequence (for example, centromes or difficult to
sequence regions. Normalized coverage was determined
by the log2 coverage within a 100 bp bin over the overall
modal coverage. We then reported the difference between
the germline and tumor normalized coverage by a sliding
window of size 2 kb. Deleted and amplified regions were
flagged by a departure of greater than 0.75 from baseline.
Moderate deletions were identified by a similar method
utilizing sequence coverage rather than clonal coverage for
consensus coding sequence exons only.
In anomalous read-pair analysis, we used perl scripts to
detect enrichment of anomalously mapping read-pairs.
These would be read-pairs that deviate from the expected
mate-pair orientation of both reads occurring in the same
direction or read-pairs that are outside the expected 1.5 kb
insert size. A series of customized perl scripts were
employed in the detection of translocation. These scripts
used SAMtools [10] internally to access the BAM files.
The analysis itself was made up of two steps. The first was
the detection of a potential translocation in both tumor
and germline samples. The second was comparison of a
potential translocation in tumor to those detected in the
germline sample to weed out potential false positives for
statistical identification of outliers. The genome was ana-
lyzed by a walker with step size equivalent to the insert
size where the number of anomalous reads was counted,
that is, those reads whose mates align on a different chro-
mosome. For each window we chose the highest hit to be
the chromosome to which mates of most of the discordant
reads mapped. We compared the ratios of discordant
reads to the total aligned reads across all the windows to
detect potential outliers. Outlier detection was done under
the assumption that the normal distribution of the propor-
tion of hit discordant reads in 2 kb windows aggregated
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across the chromosome will follow a normal distribution.
We then computed the mean of the distributions and
chose a cutoff of 3 standard deviations. The window with
a proportion of hit discordant reads higher than this cutoff
contained the region of potential translocation. The actual
region of translocation is then determined by the span of
the hit discordant reads in the window. For somatic trans-
locations, the germline and the tumor sample are called
separately and regions of overlap are eliminated. The out-
put is a general feature format (gff) file of paired lines
where the source tag indicates which two genomic regions
show potential translocations. These regions were further
inspected to reduce false positives and arrive at the more
confident list. Additional details related to the methods for
detection of somatic translocations and intrachromosomal
rearrangements are included in Additional file 1.
Validation of next generation sequencing findings
Briefly, ten single nucleotide variants and one local
deletion were selected at random for chain termination
sequencing (Sanger method). Validation was conducted
using tumor DNA. Specific genomic primer pairs
(Additional file 2) were designed to anneal in flanking
single nucleotide variant regions and approximately 150
to 500 bp fragments to be amplified in 25-cycle PCR.
Some primers carried M13 sequences on the 5’ end as a
back up for sequencing runs. Reaction products were
column purified using a QIAquick PCR Purification kit
(Qiagen) and submitted to the Arizona State University
sequencing facility. Electropherograms were then manu-
ally examined for the presence of mutations/deletions in
both orientations (Additional file 3).
Genomic quantitative PCR was performed to validate
homozygous PTEN (phosphatase and tensin homolog)
deletion (Additional file 4). In addition to the PTEN locus,
genes located in adjacent regions of hemizygous deletion
(RGR (retinal G protein coupled receptor) and HHEX
(hematopoietically expressed homeobox)) were also mea-
sured. BICC1 (bicaudal C homolog 1 (Drosophila)) and
TRUB1 (TruB pseudouridine (psi) synthase homolog 1),
located in unaffected regions of chromosome 10, were
used as internal controls. Quantitative PCR reactions were
set up in a 384-well plate in triplicate with 3 ng of
genomic DNA input per reaction. Amplifications were
performed using a LightCycler480 instrument and SYBR-
Green I Master Mix (Roche). Melting curves were exam-
ined for the presence of a single peak and Ct values were
used in calculating fold-change according to the CT
method [11]. All tumor and normal CT values were first
normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). The quantity of genomic material present for
each gene in the tumor sample was then normalized to its
normal counterpart.
Results
The patient is a 63-year-old Caucasian man diagnosed
with adenocarcinoma of the ampulla of Vater. The
patient had a Whipple procedure to resect the head of
the pancreas, distal stomach duodenum, distal common
bile duct, and gallbladder. The maximum dimension of
the tumor, which was present at the junction of the
ampullary and duodenal mucosa was 1.5 cm. The tumor
invaded into the duodenal muscle wall but no lymphatic
or vascular invasion was noted. There was no evidence of
neoplasm of the lines of resection and there was no evi-
dence of metastatic carcinoma to the 16 peripancreatic
lymph nodes examined microscopically (pathologic TNM
(Tumor, Node, Metastasis) stage T2, N0, M0). The
patient’s past history is significant of having smoked one
to two packs per day for 15 years, stopping approximately
16 years before the diagnosis of his adenocarcinoma of
the ampulla of Vater.
Massively parallel whole-genome sequencing was per-
formed on genomic DNA from germline and tumor sam-
ples using the Life Technologies SOLiD™ version 4.0
mate-pair chemistry. Basic sequence run statistics based
on our analysis pipeline are provided in Table 1. A total of
2.38 and 2.21 billion uniquely mappable reads were gener-
ated from germline and tumor DNA, which equates to
108 Gb and 100 Gb of uniquely mappable sequence for
germline and tumor, respectively. Therefore, we achieved
37× and 40× genome coverage for tumor and germline,
respectively. We detected a total of 2,771,201 SNPs from
the germline genome, 91% of which are present in dbSNP
(release 129). The transition to transversion ratio was 2.12,
which is inline with what would be expected in a diploid
human genome [12]. The full genome has been deposited
in the database of Genotypes and Phenotypes (dbGaP) of
the National Center for Biotechnology Information
(submission ID SRA 053213).
To discover somatic mutations within ampullary can-
cer, we used a custom paired analysis pipeline. The over-
view of somatic alterations within this tumor is provided
in the form of a Circos plot (Figure 1). Our paired analy-
sis revealed 19,143 genome-wide somatic point muta-
tions, of which 30 map within known annotated coding
sequences. A list of all somatic missense (n = 28) and
nonsense mutations (n = 2) is provided in Table 2. The
most notable mutation is an activating KRAS (Kirsten rat
sarcoma viral oncogene homolog) mutation at codon 12
(G12V), which is one of the most commonly reported
mutations in ampullary carcinomas [13,14]. Furthermore,
we discovered three somatic small insertions and dele-
tions within coding regions, which result in frameshift
mutations (Table 2). All missense mutations were
assessed for likely functional consequences using the
SIFT prediction algorithm [15,16], which characterized
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mutations as tolerated or damaging. Of the 28 missense
mutations that were assessed, 19 (68%) were predicted to
be damaging. Previously, we calculated the rate of SIFT
damaging calls from a random set of approximately
10,000 missense variants from the 1000 Genomes data,
which showed a rate of damaging mutations of 15%.
Validation by Sanger sequence analysis is presented in
Additional file 3.
To identify regions of somatic copy number loss, we
utilized a basic algorithm that determined log2 ratios in
Table 1 Basic sequencing statistics
Genome Number of uniquely
mapping 50 bp reads
Number of uniquely
mapping bases
Genome
coverage
Number of
germline variants
Uniquely mapping
tag pairs
Read-pair
coverage
Germline 2,383,981,557 108,322,420,859 40 2,771,201 887,285,914 443
Tumor 2,215,368,333 100,400,536,852 37 - 863,886,211 432
Read pair coverage = (Number of uniquely mappable tag-pairs) × (Insert length)/Haploid genome size.
Figure 1 Circos plot summarizing somatic events contained within pancreatic tumor of the ampulla of Vater. The outer ring shows gene
symbols for those genes somatically altered in the tumor relative to their map position against the human genome chromosome karyotype.
Blue tick marks denote genes containing nonsynonymous point mutations. Cyan tick marks denote genes containing coding indels. Magenta
tick marks represent discordant read pairs supporting putative translocation events and those genes involved in breakpoints. The inner ring
represents somatic copy number events with regions of gain shown in red and regions of loss shown in green, with brighter colors denoting
higher degrees of gain or loss. Magenta lines in the center represent breakpoint regions for translocation events.
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coverage difference between tumor and germline over a
sliding window of 4,000 bp. Regions of copy number gain
or loss are shown in Figure 1. This tumor exhibited whole
chromosome copy number gains of chromosomes 2 and
8, along with copy number loss of chromosome 19. Of
most significance was an approximate 20 Mb interstitial
deletion at 10q23, which also contained a more focal
region (2 Mb) of homozygous loss that encompassed the
PTEN tumor suppressor gene (Figure 2). No other regions
of focal gain or amplification were detected in this tumor
(validation data are presented in Additional file 4).
To identify potential cis chromosomal rearrangements
and translocation events, we searched for significant
evidence of discordant mate pairs. The long insert mate
pairs provide improved power for detecting structural
alterations through improved clonal coverage. Clonal
coverage can be defined as the genomic coverage (that is,
30×) multiplied by the length of the insert (1,500 bp),
divided by the amount of sequence derived from each
mate pair (100 bp). For example, at 37× genomic coverage
for our tumor specimen and with 1,500 bp average mate-
pair insert size, and with 2 × 50 bp mate-pairs (or 100 bp
total), we achieve a clonal coverage of 432×. With such
high clonal coverage we have significant power to detect
evidence of discordant mate-pair reads, where the length
of the insert deviates substantially from the mean insert
length and/or map to different chromosomes or chromo-
somal regions. Utilizing an algorithm that identified dis-
cordant mate-pairs specific to the tumor, we discovered
two independent translocation events occurring in the
tumor. Both events involve genes on each side of the
translocation event. One event is evidenced by significant
Table 2 List of somatic coding point mutations and small indels
Genomic position and allelesa Gene ID Codon change Amino acid consequence SIFT prediction
Chr1:71831141G/A NEGR1 503C>T T168I Damaging
Chr1:149227247C/T ANXA9 760C>T R245C Damaging
Chr1:156702726C/A OR10K1 751C>A H251N Damaging
Chr1:220801358G/T TAF1A 1211C>A A404D Damaging
Chr1:226621463T/G OBSCN 19592T>G F6531C Not scored
Chr1:238137913G/A CHRM3 539G>A R180Q Damaging
Chr2:49235000G/A FSHR 61C>T R21W Tolerated
Chr2:165735207G/C SCN3A 362C>G A121G Damaging
Chr2:178905886C/T OSBPL6 529C>T R177X -
Chr3:109658364C/T MYH15 2137G>A G713R Damaging
Chr3:129258301T/G SEC61A1 280T>G L94V Damaging
Chr4:6670038G/A MAN2B2 2732G>A R911H Tolerated
Chr6:28336272A/G NKAPL 1144A>G S382G Damaging
Chr7:2599270C/T IQCE 1333C>T R445X -
Chr7:43813258G/A BLVRA 790G>A G264S Tolerated
Chr8:76091857G/T CRISPLD1 950G>T C317F Damaging
Chr9:33301117G/A NFX1 1240G>A G414R Damaging
Chr10:17777173T/C STAM 364T>C Y122H Damaging
Chr10:99328071C/T ANKRD2 274C>T R92W Damaging
Chr11:6368506-6368518del SMPD1 102-114del L35WfsX72 -
Chr11:92170718A/T FAT3 4894A>T M1632L Not scored
Chr11:116661033A/T RNF214 2068A>T T690S Not scored
Chr12:1854754C/T CACNA2D4 1730G>A G577E Damaging
Chr12:5902149C/A ANO2 93G>T Q31H Damaging
Chr12:25289551C/A KRAS 35G>T G12V Damaging
Chr14:19598288-19598307del OR4L1 245-264del I82TfsX104 -
Chr15:32142462G/A CHRM5 252G>A M84I Damaging
Chr15:83002258G/C NMB 130C>G H44D Tolerated
Chr17:11543819G/A DNAH9 4919G>A R1640Q Tolerated
Chr17:41416912C/G MAPT 905C>G T302R Damaging
Chr18:42815392C/T TCEB3B 242G>A R81Q Tolerated
Chr18:46845916C/T SMAD4 1081C>T R361C Damaging
Chr20:25405049-25405055del NINL 2872-2878del W958HfsX960 -
aReference allele/mutated allele.
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discordant read pairs in the tumor mapping to the
LINGO2 (leucine rich repeat and Ig domain containing 2)
locus at 9q21.1 (chr9: 27990017-27991975), which is trans-
located to the TTC28 (tetratricopeptide repeat domain 28)
locus at 22q12.1 (chr22: 27401302-27401562) (Figure 1).
A second event is evidenced by discordant mate-pair read
mapping to the PRIM2 (primase, DNA, polypeptide 2)
locus at 6p12.1 (chr6: 57450028- 57451992) and to the
Figure 2 Zoom in of the 10q region containing focal homozygous deletion encompassing the PTEN tumor suppressor gene.
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NPAS3 (neuronal PAS domain protein 3) locus at 14q13.1
(chr14: 33206124- 33207653) (Figure 1).
Discussion
Adenocarcinomas of the ampulla of Vater are relatively
rare, accounting for only 0.2% of gastrointestinal cancers
[17]. Perhaps due to their location and propensity to pre-
sent with jaundice at an early resectable stage, these
tumors are more likely to be resectable at the time of
diagnosis than are pancreatic cancers [18]. Furthermore,
in comparison to pancreatic cancer, resected ampullary
cancers are associated with better 5-year survival rates of
34 to 61% [19-21]. Surgical series have demonstrated the
factors affecting survival include completeness of surgical
resection and nodal status. Surgical treatment for ampul-
lary cancer and cancers in the head of the pancreas are
similar in that surgeons perform a pancreaticoduodenect-
omy. Thereafter, the treatments may diverge. There is no
clear consensus on the role of or the optimal regimen for
adjuvant chemotherapy in ampullary cancers. Similarly,
in part due to its relative rarity, there is no clear standard
chemotherapeutic regimen for recurrent or metastatic
ampullary cancer.
A better understanding of molecular oncogenesis and
the emergence of targeted agents will likely lead to
improved treatment outcomes in this and other cancers.
Our study used whole genome sequencing to analyze the
genome of a resected ampullary carcinoma. We found
expected as well as novel aberrations. We found an acti-
vating mutation in KRAS codon 12. KRAS mutations are
common in ampullary cancer although the 25 to 37%
incidence appears to be lower than the approximately
95% rate of KRAS mutation seen in pancreatic adenocar-
cinomas [13,14,22,23]. Furthermore, similar to what is
seen in colonic adenomas, KRAS mutations occur in
benign ampullary adenomas, suggesting activating muta-
tions of KRAS are relatively early events in the progres-
sion toward cancer and the mutation does not appear to
affect prognosis [14]. This tumor also demonstrated a
somatic nonsynonymous mutation in SMAD4 (mothers
against decapentaplegic homolog 4), which has been
observed previously in 50% of ampullary cancers but
infrequently in bile duct cancers [24].
The most notable gene deletion we found was a focal
deletion of a region in chromosome 10 including the PTEN
tumor suppressor gene (phosphate and tensin homologue
deleted on chromosome 10). Cowden’s syndrome is charac-
terized by a germline mutation in the PTEN gene resulting
in loss of function. This syndrome is characterized by non-
cancerous hamartomas of the skin and mucous membranes
and affected patients have in increased risk of tumors of the
breast, thyroid, uterus and gastrointestinal tract. Benign
tumors of the ampulla of Vater have been reported in
patients with Cowden’s syndrome but are not a common
feature within cancers of the ampulla. Loss of PTEN
expression by immunohistochemisty has been associated
with liver metastases and poor prognosis in colon cancer
[25]. In a large-scale survey of the genomic aberrations of
pancreatic cancers, PTEN deletions were not seen, although
small deleterious coding mutations were detected [26].
We can conclude that despite their anatomic location in
proximity to the pancreas, ampullary cancers are distinct
entities from adenocarcinoma of the pancreas and bile duct
cancers and thus should be treated as a different entity.
To that end, the loss of PTEN expression is important
not only in the pathogenesis but because it exposes a
potential therapeutic target (Figure 3). The PTEN protein
product is an inhibitor of phosphoinositide 3-kinase
(PI3K) and downstream signaling through AKT. Phos-
phorylation of Akt results in phosphorylation of several
target proteins involved in regulation of key cellular func-
tions, including cell proliferation, glucose metabolism,
protein translation, and cell survival [27]. Additionally,
activation of the PI3K pathway has been linked to activa-
tion of mammalian target of rapamycin (mTOR), although
the mechanism is not yet fully elucidated [28]. The pre-
sence of a deletion in PTEN in this ampullary cancer
would be predicted to release from inhibition activation of
the PI3K/mTOR pathway. Consequently, one can infer
that an agent that is a dual PI3K/mTOR inhibitor, such as
NVP-BEZ235, would be an attractive therapeutic option
for our patient should his disease recur [29]. NVP-BEZ235
and other agents like it have been shown in vitro to inhibit
growth of cancer cells with activating mutations of PI3K
and are all under clinical development [30]. In the case
presented here, however, the tumor carries both a KRAS
activating mutation and complete inactivation of PTEN,
supporting dual activation of both the MEK/ERK and the
PI3K/AKT axes (Figure 3). The inhibition of only one axis
may not be sufficient for effective treatment as there is
likely to be compensatory activity from the other activated
axis.
Our group reported the beneficial results seen in a
clinical trial on patients with refractory solid tumors
whose chemotherapy was chosen based on analysis of
tumor biopsies using immunohistochemistry and expres-
sion arrays [31]. New technologies such as applied herein
have made high-throughput whole-genome sequencing a
more rapid and cost-effective process in a manner not
possible with older technologies such as Sanger sequen-
cing. The prospect is raised, therefore, that one may soon
be able to apply whole-genome sequencing to the analy-
sis of an individual patient’s tumor to guide an informed
choice of a therapeutic regimen. This type of persona-
lized or precision medicine has only begun to be studied.
Several limitations remain before this whole-genome
sequencing methodology can be widely applied, including
the need for improved and standardized bioinformatic
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analysis, along with reliable and rapid methods for valida-
tion of genomic findings and cost. Furthermore, if a tar-
get is found, one must have access to an agent and, in
many cases, such agents may not be approved for clinical
use. Thus, we must begin to understand the links
between genomic profile and drug context in early drug
development. This is amplified even more where there is
evidence to support combination therapies.
Conclusions
We have analyzed the whole genome sequence of a cancer
of the ampulla of Vater to uncover the compendium of
somatic events occurring in this tumor. Among the muta-
tions discovered were those that might be considered
potential therapeutic vulnerabilities. As whole-genome
sequencing becomes more rapid and less expensive, the
potential for targeted and truly personalized treatments
increases. Consequently, as we continue to refine our abil-
ities to uncover the full landscape of somatic alterations,
we must in parallel continue innovative drug development
methods, including preclinical and early phase I combina-
tion trials. This will allow us to understand toxicities and
appropriate dosing regimens, to obtain the safest and most
appropriate combinations matched to specific genomic
and molecular contexts.
Additional material
Additional file 1: Supplemental methods giving additional details
regarding the methods used for the detection of somatic
translocations and intrachromosomal rearrangements.
Additional file 2: Validation primer sets: sequencing and
quantitative PCR primer pairs used in validation of next generation
sequencing results.
Additional file 3: Figure showing the results of validation by Sanger
sequencing: validation of single nucleotide variants (n = 10) and a
local deletion. Sequencing electropherograms depicting specific
mutations in selected genes in forward and reverse orientations.
Additional file 4: Figure demonstrating the validation of the next
generation sequencing comparative genomic hybridization findings
of a PTEN deletion. Results depicted show the relative fold changes
measured by quantitative PCR in tumor versus normal genomic DNA in
specific regions of chromosome 10q affected by hemi- (RGR and HHEX)
or homozygous (PTEN) deletion.
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